Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis
Masahiro Torasawa, Tatsuya Yoshida, Shigehiro Yagishita, Yukiko Shimoda, Masayuki Shirasawa, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Kazuhisa Takahashi, Yuichiro Ohe
Topics & Concepts
NivolumabPembrolizumabMedicineHazard ratioInternal medicinePropensity score matchingLung cancerConfidence intervalOncologyAdverse effectSubgroup analysisCancerImmunotherapyCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentFerroptosis and cancer prognosis